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Background: The Eastern Co-operative Oncology Group (ECOG) 
4599 phase III trial demonstrated that the addition of bevacizumab 
to carboplatin/paclitaxel (CP) signiﬁcantly improved overall survival 
and progression-free survival (PFS) in patients with advanced non-
squamous non-small cell lung cancer (NSCLC) [Sandler et al., NEJM 
2006;355:2542-50]. Cisplatin/gemcitabine (CG) is a combination com-
monly used in Europe and other regions outside of the USA. In order 
to establish the efﬁcacy of bevacizumab in combination with cisplatin-
based doublets, the BO17704 trial investigated the effect of the addition 
of bevacizumab to CG on PFS in patients with advanced NSCLC.
Methods: This randomised, placebo-controlled, multicentre 3-arm 
phase III study compared the efﬁcacy of two doses of bevacizumab in 
combination with CG versus CG plus placebo. The primary endpoint 
was to demonstrate superiority in PFS in both bevacizumab-contain-
ing treatment arms versus the control regimen. Secondary endpoints 
were overall survival, response rate and safety. Eligibility criteria were 
histologically or cytologically documented previously untreated locally 
advanced, metastatic or recurrent non-squamous NSCLC; ECOG per-
formance status 0-1; adequate haematological, renal and liver function; 
no brain metastases; no history of recent CTC grade ≥2 haemoptysis. 
Between February 2005 and August 2006, a total of 1,043 patients were 
randomised 1:1:1 to three treatment groups. One group received up to 
6 cycles of C 80mg/m2 on day 1 and G 1,250mg/m2 on day 1 and day 
8 every 3 weeks plus placebo (n=347). The second group received CG 
chemotherapy plus bevacizumab at a dose of 7.5mg/kg every 3 weeks 
(n=345), and the third group received CG chemotherapy plus beva-
cizumab at a dose of 15mg/kg every 3 weeks (n=351). Bevacizumab 
was to be administered until disease progression for both bevacizumab 
arms. Data cut-off was two months after the last patient was enrolled.
Results: Bevacizumab at a dose of 7.5 or 15mg/kg every 3 weeks in 
combination with CG chemotherapy signiﬁcantly prolonged PFS in pa-
tients with advanced NSCLC when compared with CG chemotherapy 
plus placebo. The treatment effects observed in the two bevacizumab-
containing arms were similar. No new safety signals associated with the 
use of bevacizumab were observed for either bevacizumab dose in this 
clinical setting.
Conclusions: The trial met its primary endpoint. Final efﬁcacy and 
safety results for each arm will be presented at the meeting.
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Background: Acquired resistance to geﬁtinib in NSCLC patients 
with somatic activating EGFR mutations has been associated with 
the development of a secondary T790M mutation in about 50% of the 
patients. The mechanisms for acquired resistance in the remaining 
tumors are still unknown. Heat shock protein 90 (Hsp90) is a molecular 
chaperone that plays a key role in the conformational maturation of 
oncogenic signaling proteins and has become an exciting therapeutic 
target for the treatment of cancer. IPI-504, the highly soluble hydro-
quinone hydrochloride derivative of 17-AAG, was synthesized as an 
Hsp90 inhibitor with favorable pharmaceutical properties. Herein, we 
explored new therapeutic strategies overcoming the EGFR T790M and 
non-T790M geﬁtinib-resistance mechanisms. Methods and Results: We 
have developed geﬁtinib-resistant (GR) clones from geﬁtinib-hyper-
sensitive EGFR L858R mutant (H3255) and EGFR exon 19 deletion 
(del E746_A750) mutant (HCC827) NSCLC cell lines by exposing 
them to increasing concentrations of geﬁtinib in vitro. Analyses of the 
resistant cells demonstrate that H3255 GR contain an EGFR T790M 
mutation which is not observed in HCC827 GR cells. We investigated 
the effects of IPI-504 on cells according to the mechanism of resistance 
to geﬁtinib; KRAS mutation (A549 and H441), EGFR T790M mutation 
(H1975 and H3255GR) and non-T790M mutation (HCC827GRs). In 
time course experiments, mutant EGFR proteins in H1975, H3255GR 
and HCC827GRs were depleted after only 6 hrs of exposure to 100 
nM IPI-504, while diminution of wild-type EGFR in A549 and H441 
was less substantial. However, several client proteins for Hsp90 were 
equally affected among these cell lines. Exposure to IPI-504 showed 
dose and time dependent growth inhibition exhibiting IC50 values for 
cell viability at 72 h that ranged from 41 - 293nM. All cell lines tested 
were found to be sensitive to IPI-504 regardless of geﬁtinib-resistance 
mechanisms. When geﬁtinib was combined, IPI-504 also showed 
synergism with Combination Indices (CI) at the IC50 and further stud-
ies are ongoing to evaluate for potential synergy with geﬁtinib. Flow 
cytometric Tunel assay and ﬂuorescent-based casspase 3/7 in H1975, 
H3255GR and HCC827GR with mutant EGFR showed that the 48 hr 
treatment with 1.0uM IPI-504 caused an increase in sub-G1 fraction 
and apoptosis. 
Conclusions: These data support the conclusion that mutational activa-
tion of EGFR is associated with dependence on Hsp90 for stability. 
Taken together, IPI-504 represents a novel strategy for the treatment 
of NSCLC patients having EGFR T790M or non-T790M geﬁtinib-re-
sistance mechanism and suggests an important implication for clinical 
development.
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Study Objective: Protocols using indction chemotherapy for advanced 
lung cancer are more frequently used with the hope that surgery can be 
performed after the cancer is downstaged. The current restaging mo-
dalities either have a low diagnostic accuracy (computed tomography) 
or can be technically difﬁcult (Re-, mediastinoscopy). Endobronchial 
ultrasound guided TBNA is an excellent tool for mediastinal lymph 
node staging and may have a role in restaging also. 
